COVID-19: Monoclonal antibody therapy 100 per cent prevents severe disease and deaths, says study
PTI, Nov 3, 2021, 9:14 AM IST
Monoclonal therapy reduces severe disease and death in high-risk individuals infected with the Delta variant of SARS CoV2 by 100 per cent, according to a new study.
”In the world’s first published study in a peer reviewed, high impact journal, AIG Hospitals along with the Asian Healthcare Foundation, CCMB Hyderabad and Institute of Life Sciences, successfully proved that the Monoclonal Therapy reduces severe disease and death in high-risk individuals infected with the Delta Variant of SARS CoV 2 by 100 per cent,” the city-based AIG hospitals said in a release here on Tuesday.
The key highlights from the study include — More than 98 per cent samples tested were identified as the Delta Variant, 75 per cent patients who got the Monoclonal Therapy became RT-PCR Negative by seventh day and 78 per cent patients got relieved of their clinical symptoms like fever, cough, etc. by seventh day.
The other highlights are that none of the study participants developed severe disease or died and there was no increase in inflammatory markers in these patients which causes severe disease, the release said.
The highlights also include — on follow up, none of the patients reported any post-COVID symptom and the neutralising activity of the Monoclonal Therapy was similar in both the original Wuhan Strain and the Delta Strain, it said.
”The results are astonishing and will shape the public health policy for treatment of COVID-19 especially in high-risk individuals, those above age of 60 or even below 60 but with diabetes, hypertension, obesity, pregnant woman, people with chronic diseases, all will benefit immensely,” said D Nageshwar Reddy, Chairman, AIG Hospitals.
”We have clearly demonstrated in our research that when given at the right time, Monoclonal Therapy stops the progression of the disease completely,” he said.
The AIG Hospitals and its research arm, the Asian Healthcare Foundation conceptualized, designed, and funded the study. The patients were recruited from Fever Clinic at AIG Hospitals, the release said.
The Centre for Cellular and Molecular Biology (a unit of CSIR) was involved in sequencing the genome of the virus strains collected to identify and confirm the Delta Variant and the Institute of Life Sciences, University of Hyderabad tested the neutralising activity of the cocktail against the delta variant in their lab, it said.
The study was conducted on 285 high-risk individuals and published in the International Journal of Internal Medicine, the release said.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Study shows how brain chemicals control eating, could help develop improved obesity drugs
‘Faster walkers’ had significantly lower risk of diabetes, hypertension: Study
World Meditation Day 2024: Celebrating inner peace and well-being
Virus causing gut infections could play role in development of Alzheimer’s: Study
Air pollution linked to more hospitalisations for all causes, mental illness too, study finds
MUST WATCH
Latest Additions
Derogatory comments row: K’taka Minister Hebbalkar dares BJP’s Ravi to take oath before god
Aaditya requests Fadnavis to make cities free of political banners, assures support
Kohli needs to resist flashing outside the off-stump: Hayden
KSRTC inducts 20 Ambaari Utsav sleeper buses
IRCTC has stopped paying compensation to passengers for delay in private trains: RTI
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.